61 related articles for article (PubMed ID: 30014884)
1. Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis.
Pelzer U; Wislocka L; Jühling A; Striefler J; Klein F; Roemmler-Zehrer J; Sinn M; Denecke T; Bahra M; Riess H
Eur J Cancer; 2018 Sep; 100():85-93. PubMed ID: 30014884
[TBL] [Abstract][Full Text] [Related]
2. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.
De Vita F; Ventriglia J; Febbraro A; Laterza MM; Fabozzi A; Savastano B; Petrillo A; Diana A; Giordano G; Troiani T; Conzo G; Galizia G; Ciardiello F; Orditura M
BMC Cancer; 2016 Sep; 16(1):709. PubMed ID: 27590845
[TBL] [Abstract][Full Text] [Related]
3. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
Portal A; Pernot S; Tougeron D; Arbaud C; Bidault AT; de la Fouchardière C; Hammel P; Lecomte T; Dréanic J; Coriat R; Bachet JB; Dubreuil O; Marthey L; Dahan L; Tchoundjeu B; Locher C; Lepère C; Bonnetain F; Taieb J
Br J Cancer; 2015 Sep; 113(7):989-95. PubMed ID: 26372701
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.
Ko AH; Murphy PB; Peyton JD; Shipley DL; Al-Hazzouri A; Rodriguez FA; Womack MS; Xiong HQ; Waterhouse DM; Tempero MA; Guo S; Lane CM; Earwood C; DeBusk LM; Bendell JC
Oncologist; 2017 Dec; 22(12):1427-e129. PubMed ID: 28935773
[TBL] [Abstract][Full Text] [Related]
5. Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study.
Chang C; Li X; Cao D
BMC Cancer; 2021 May; 21(1):545. PubMed ID: 33985455
[TBL] [Abstract][Full Text] [Related]
6. Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer.
Kokkali S; Tripodaki ES; Drizou M; Stefanou D; Magou E; Zylis D; Kapiris M; Nasi D; Georganta C; Ardavanis A
In Vivo; 2018; 32(3):653-657. PubMed ID: 29695574
[TBL] [Abstract][Full Text] [Related]
7. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.
Seufferlein T; Uhl W; Kornmann M; Algül H; Friess H; König A; Ghadimi M; Gallmeier E; Bartsch DK; Lutz MP; Metzger R; Wille K; Gerdes B; Schimanski CC; Graupe F; Kunzmann V; Klein I; Geissler M; Staib L; Waldschmidt D; Bruns C; Wittel U; Fichtner-Feigl S; Daum S; Hinke A; Blome L; Tannapfel A; Kleger A; Berger AW; Kestler AMR; Schuhbaur JS; Perkhofer L; Tempero M; Reinacher-Schick AC; Ettrich TJ
Ann Oncol; 2023 Jan; 34(1):91-100. PubMed ID: 36209981
[TBL] [Abstract][Full Text] [Related]
8. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study.
Ueno M; Morinaga S; Hashimoto Y; Umemoto K; Sasahira N; Saiura A; Seyama Y; Honda G; Ioka T; Takahashi H; Miyamoto A; Nakamori S; Unno M; Takadate T; Mizuno N; Shimizu Y; Ueno H; Sugiyama M; Fukutomi A; Shimizu S; Okusaka T; Furuse J
Pancreas; 2021 Jan; 50(1):83-88. PubMed ID: 33370027
[TBL] [Abstract][Full Text] [Related]
9. Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer.
Nakano S; Komatsu Y; Kawamoto Y; Saito R; Ito K; Nakatsumi H; Yuki S; Sakamoto N
Medicine (Baltimore); 2020 Sep; 99(39):e22250. PubMed ID: 32991420
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer.
Hoffman RM; Bouvet M
Expert Opin Pharmacother; 2015 May; 16(7):943-7. PubMed ID: 25887245
[TBL] [Abstract][Full Text] [Related]
11. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
Davis SL; Cardin DB; Shahda S; Lenz HJ; Dotan E; O'Neil BH; Kapoun AM; Stagg RJ; Berlin J; Messersmith WA; Cohen SJ
Invest New Drugs; 2020 Jun; 38(3):821-830. PubMed ID: 31338636
[TBL] [Abstract][Full Text] [Related]
12. Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma.
Tian Z; Zhang F; Li P; Wang J; Yang J; Zhang P; Yao W; Wang X
BMC Cancer; 2020 Jul; 20(1):698. PubMed ID: 32723378
[TBL] [Abstract][Full Text] [Related]
13. Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy.
Hohmann N; Sprick MR; Pohl M; Ahmed A; Burhenne J; Kirchner M; Le Cornet L; Kratzmann M; Hajda J; Stenzinger A; Steindorf K; Delorme S; Schlemmer HP; Riethdorf S; van Schaik R; Pantel K; Siveke J; Seufferlein T; Jäger D; Haefeli WE; Trumpp A; Springfeld C
Clin Transl Sci; 2023 Dec; 16(12):2483-2493. PubMed ID: 37920921
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine.
D'Angelo A; Catalano M; Conca R; Petrioli R; Siminonato F; Cappetta A; Roviello G; Ramello M
J Chemother; 2023 Dec; 35(8):753-759. PubMed ID: 37167100
[TBL] [Abstract][Full Text] [Related]
15. Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Ishizaki A; Okuwaki K; Kida M; Imaizumi H; Iwai T; Yamauchi H; Kaneko T; Hasegawa R; Watanabe M; Kurosu T; Ishizaki J; Kusano C
Intern Med; 2023 Oct; 62(19):2783-2793. PubMed ID: 36792197
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of gemcitabine in combination with nanoparticle albumin-bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review.
Kase AM; Azzouqa AG; Kochuveettil S; Colon-Otero G
Cancer Med; 2023 Apr; 12(8):9434-9438. PubMed ID: 36806695
[TBL] [Abstract][Full Text] [Related]
17. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma.
Gasparini G; Aleotti F; Palucci M; Belfiori G; Tamburrino D; Partelli S; Orsi G; Macchini M; Archibugi L; Capurso G; Arcidiacono PG; Crippa S; Reni M; Falconi M
Dig Liver Dis; 2023 Dec; 55(12):1750-1756. PubMed ID: 37121820
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of Increased Skeletal Muscle Mass During Nab-Paclitaxel Plus Gemcitabine Treatment in Patients With Advanced Pancreatic Cancer.
Iede K; Yamada T; Ishida T; Tsuda Y; Nakashima S; Tanida T; Matsuyama J; Nakata K; Tominaga S
Pancreas; 2024 Jan; 53(1):e22-e26. PubMed ID: 38157455
[TBL] [Abstract][Full Text] [Related]
19. RE: nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial.
Palani Velu LK; Steele CW; Dickson EJ; Carter CR; McKay CJ; Horgan PG; McMillan DC; Jamieson NB
J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26251329
[No Abstract] [Full Text] [Related]
20. Suppression of hypoxia-induced CAV1 autophagic degradation enhances nanoalbumin-paclitaxel transcytosis and improves therapeutic activity in pancreatic cancer.
Bai X; Xiong J; Li L; Yu C; Sun C
Eur J Pharmacol; 2024 Apr; 969():176431. PubMed ID: 38395374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
